

Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Section 1: Identification

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908

Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800

CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye irri-

tation

Category 2

Reproductive toxicity : Category 1

Specific target organ toxicity - :

single exposure (Oral)

Category 2 (Central nervous system)

Specific target organ toxicity - :

single exposure

Category 3

Specific target organ toxicity - :

repeated exposure

Category 2 (Central nervous system)

Hazardous to the aquatic environment - acute hazard

Category 1



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

Hazardous to the aquatic environment - chronic hazard

Category 1

GHS label elements

Hazard pictograms







Signal word : Dange

Hazard statements : H302 + H332 Harmful if swallowed or if inhaled.

H315 Causes skin irritation.

H319 Causes serious eye irritation. H335 May cause respiratory irritation.

H360Df May damage the unborn child. Suspected of damaging

fertility.

H371 May cause damage to organs (Central nervous system) if

swallowed.

H373 May cause damage to organs (Central nervous system)

through prolonged or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe mist or vapours.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P271 Use only outdoors or in a well-ventilated area.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P302 + P352 IF ON SKIN: Wash with plenty of water.

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/

doctor if you feel unwell.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and

easy to do. Continue rinsing.

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor.

P332 + P313 If skin irritation occurs: Get medical advice/ atten-

tion.

P337 + P313 If eye irritation persists: Get medical advice/ at-

tention.

P391 Collect spillage.

Storage:



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1210015-00024 10.0 06.04.2024 Date of first issue: 10.01.2017

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--|------------|-----------------------|
| N-Methyl-2-pyrrolidone | 872-50-4 | >= 20 -< 30 |
| Ivermectin | 70288-86-7 | >= 1 -< 2.5 |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 | >= 1 -< 2.5 |
| (dl)-a-Tocopheryl acetate | 7695-91-2 | < 0.1 |

Section 4: First-aid measures

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

> If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of contact, immediately flush skin with plenty of water In case of skin contact

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of contact, immediately flush eyes with plenty of water In case of eye contact

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms

and effects, both acute and

delayed

Harmful if swallowed or if inhaled.

Causes skin irritation.

Causes serious eye irritation. May cause respiratory irritation.

May damage the unborn child. Suspected of damaging fertili-



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

May cause damage to organs if swallowed.

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection.

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire-

fighting

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

In the event of fire, wear self-contained breathing apparatus.

SO.

Evacuate area.

Special protective equipment

for firefighters

en .

Use personal protective equipment.

Hazchem Code : 3Z

Section 6: Accidental release measures

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and dis-



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

Section 7: Handling and storage

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

| Components | CAS-No. | Value type | Control parame- | Basis |
|------------|---------|------------|-----------------|-------|
| | | | | |



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

| | | (Form of exposure) | ters / Permissible concentration | |
|--|--------------------------------------|--------------------|----------------------------------|----------|
| N-Methyl-2-pyrrolidone | 872-50-4 | WES-TWA | 10 ppm 40 mg/m3 | NZ OEL |
| | Further information: Skin absorption | | | |
| | | WES-STEL | 20 ppm 80 mg/m3 | NZ OEL |
| | Further information: Skin absorption | | | |
| Ivermectin | 70288-86-7 | TWA | 30 μg/m3 (OEB 3) | Internal |
| | Further information: Skin | | | |
| | | Wipe limit | 300 μg/100 cm2 | Internal |
| abamectin (combination of avermectin B1a and avermec- tin B1b) (ISO) | 71751-41-2 | TWA | 15 μg/m3 (OEB 3) | Internal |
| | | Wipe limit | 150 µg/100 cm ² | Internal |
| (dl)-a-Tocopheryl acetate | 7695-91-2 | TWA | 5000 ug/m3 (OEB 1) | Internal |

Biological occupational exposure limits

| Components | CAS-No. | Control parameters | Biological specimen | Sam- pling time | Permissible concentration | Basis |
|------------------------|----------|--|---------------------|--|---------------------------|--------------|
| N-Methyl-2-pyrrolidone | 872-50-4 | 5-Hydroxy- N-methyl-2- pyrrolidone | Urine | End of shift (As soon as possible after exposure ceases) | 100 mg/l | ACGIH BEI |

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type
Hand protection

: Combined particulates and organic vapour type

Material : Chemical-resistant gloves



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Section 9: Physical and chemical properties

Appearance : liquid

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : > 100 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 0.91 - 1.00 mg/l



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Solubility(ies)

Water solubility : insoluble

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous

products

No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,031 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2,000 mg/kg



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

П

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:

N-Methyl-2-pyrrolidone:

Result : Skin irritation

Ivermectin:

Species : Rabbit

Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N-Methyl-2-pyrrolidone:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact

Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Remarks : Based on data from similar materials

Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test Exposure routes : Skin contact

Result : Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type : Draize Test
Exposure routes : Skin contact
Species : Humans
Result : negative

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion Method: OECD Test Guideline 474

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Hamster

Application Route: Ingestion

Method: OECD Test Guideline 475

Result: negative

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

I

(dl)-a-Tocopheryl acetate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : inhalation (vapour)

Exposure time : 2 Years
Result : negative

Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

(dl)-a-Tocopheryl acetate:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
Result : negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

N-Methyl-2-pyrrolidone:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 414

Result: positive

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: inhalation (vapour)

Result: positive

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: positive

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop- : Test Type: Development



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

ment Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit

Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body

weight

Result: Fetotoxicity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic

survival

Remarks: Adverse developmental effects were observed



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal experi-

ments.

(dl)-a-Tocopheryl acetate:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

STOT - single exposure

May cause respiratory irritation.

May cause damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion

Target Organs : Central nervous system



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

N-Methyl-2-pyrrolidone:

Species : Rat, male

NOAEL : 169 mg/kg

LOAEL : 433 mg/kg

Application Route : Ingestion

Exposure time : 90 Days

Method : OECD Test Guideline 408

 Species
 : Rat

 NOAEL
 : 0.5 mg/l

 LOAEL
 : 1 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 96 Days

Method : OECD Test Guideline 413

Species : Rabbit

NOAEL : 826 mg/kg

LOAEL : 1,653 mg/kg

Application Route : Skin contact

Exposure time : 20 Days

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species: RatNOAEL: 0.4 mg/kgLOAEL: 0.8 mg/kgApplication Route: OralExposure time: 3 Months

Target Organs : spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):



Ivermectin / Abamectin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 10.0
 06.04.2024
 1210015-00024
 Date of first issue: 10.01.2017

Species : Rat

NOAEL : 1.5 mg/kg

Application Route : Oral

Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Mouse

NOAEL : 4.0 mg/kg

Application Route : Oral

Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

 Species
 : Dog

 NOAEL
 : 0.25 mg/kg

 LOAEL
 : 0.5 mg/kg

 Application Route
 : Oral

 Exposure time
 : 53 Weeks

Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

(dl)-a-Tocopheryl acetate:

Species : Rat

NOAEL : 500 mg/kg

Application Route : Ingestion

Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous

system effects, Salivation, tearing

Section 12: Ecological information

Ecotoxicity

Components:

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 1,000 mg/l

Exposure time: 24 h Method: DIN 38412

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l

Exposure time: 72 h

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 12.5 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 600 mg/l

Exposure time: 30 min Method: ISO 8192

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

M-Factor (Acute aquatic tox- : 10,000

icity)

M-Factor (Chronic aquatic : 10,000

toxicity)

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 μg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 µg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

ma/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

citv)

10,000

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l

Exposure time: 32 d

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.03 μg/l

Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l

Exposure time: 28 d

M-Factor (Chronic aquatic

toxicity)

10,000

Toxicity to microorganisms : EC50: > 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203



Ivermectin / Abamectin Liquid Formulation

SDS Number: Date of last issue: 30.09.2023 Version **Revision Date:** 1210015-00024 10.0 06.04.2024 Date of first issue: 10.01.2017

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l

Exposure time: 28 d

EC50: > 927 mg/l Toxicity to microorganisms

Exposure time: 30 min Method: ISO 8192

Persistence and degradability

Components:

N-Methyl-2-pyrrolidone:

Biodegradability Result: Readily biodegradable.

> Biodegradation: 73 % Exposure time: 28 d

Method: OECD Test Guideline 301C

Ivermectin:

Result: Not readily biodegradable. Biodegradability

> Biodegradation: 50 % Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability Result: Not readily biodegradable.

Biodegradation: 21.7 - 31 %

Exposure time: 28 d

Method: OECD Test Guideline 301C



Ivermectin / Abamectin Liquid Formulation

SDS Number: Date of last issue: 30.09.2023 Version Revision Date: 1210015-00024 10.0 06.04.2024 Date of first issue: 10.01.2017

Bioaccumulative potential

Components:

N-Methyl-2-pyrrolidone:

Partition coefficient: n-: log Pow: -0.46

Method: OECD Test Guideline 107 octanol/water

Ivermectin:

Bioaccumulation Bioconcentration factor (BCF): 74

Partition coefficient: nlog Pow: 3.22

octanol/water

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation Bioconcentration factor (BCF): 52

Partition coefficient: nlog Pow: 4

octanol/water

Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ: log Koc: > 3.6

mental compartments

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number UN 3082

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class Packing group Ш



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Labels : 9 Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen: 964

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

964

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Hazchem Code : 3Z
Marine pollutant : no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

not allocated

Tolerable Exposure Limits (TEL)

| | Chemical name | Environmental compartment | Reference concentration | |
|----------------------------|----------------------------|---------------------------|-------------------------|--|
| | 2-Pyrrolidinone, 1-methyl- | Air | 0.4 mg/m3 | |
| | 2-Pyrrolidinone, 1-methyl- | Drinking Water | 0.375 mg/l | |
| 2-Pyrrolidinone, 1-methyl- | | Skin/Surface Deposition | 0.83 mg/m2 | |

Environmental Exposure Limits (EEL)

| | Chemical name | | |
|---|---------------|--------------|---------------|
| Ш | ivermectin | Fresh water | 0.000001 mg/l |
| П | ivermectin | Marine water | 0.000001 mg/l |

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 06.04.2024

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospher-

ic Contaminants

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average NZ OEL / WES-STEL : Workplace Exposure Standard - Short-Term Exposure Limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for



Ivermectin / Abamectin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 10.0 06.04.2024 1210015-00024 Date of first issue: 10.01.2017

Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN